4-IBPCAS# 155798-08-6 |
2D Structure
- MK-4827
Catalog No.:BCC1761
CAS No.:1038915-60-4
- BMN-673 8R,9S
Catalog No.:BCC1422
CAS No.:1207456-00-5
- XAV-939
Catalog No.:BCC1120
CAS No.:284028-89-3
- PJ34
Catalog No.:BCC1865
CAS No.:344458-19-1
- ABT-888 (Veliparib)
Catalog No.:BCC1267
CAS No.:912444-00-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 155798-08-6 | SDF | Download SDF |
PubChem ID | 132995 | Appearance | Powder |
Formula | C19H21IN2O | M.Wt | 420.29 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 20 mg/mL (47.59 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | N-(1-benzylpiperidin-4-yl)-4-iodobenzamide | ||
SMILES | C1CN(CCC1NC(=O)C2=CC=C(C=C2)I)CC3=CC=CC=C3 | ||
Standard InChIKey | HELCSESNNDZLFM-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C19H21IN2O/c20-17-8-6-16(7-9-17)19(23)21-18-10-12-22(13-11-18)14-15-4-2-1-3-5-15/h1-9,18H,10-14H2,(H,21,23) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Combines high affinity for σ1 and moderate affinity for σ2 sites. Centrally active following systemic administration in vivo. |
4-IBP Dilution Calculator
4-IBP Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3793 mL | 11.8965 mL | 23.7931 mL | 47.5862 mL | 59.4827 mL |
5 mM | 0.4759 mL | 2.3793 mL | 4.7586 mL | 9.5172 mL | 11.8965 mL |
10 mM | 0.2379 mL | 1.1897 mL | 2.3793 mL | 4.7586 mL | 5.9483 mL |
50 mM | 0.0476 mL | 0.2379 mL | 0.4759 mL | 0.9517 mL | 1.1897 mL |
100 mM | 0.0238 mL | 0.119 mL | 0.2379 mL | 0.4759 mL | 0.5948 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
4-IBP is a selective σ1 agonist with a high level of affinity for the σ1 receptor (Ki = 1.7 nM) and a moderate affinity for the σ2 receptor (Ki = 25.2 nM) . IC50 value: 1.7 nM (Ki) Target: σ1 in vitro: 4-IBP is a σ1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells. 4-IBP is used to investigate whether targeting theσ1 receptor could modify in vitro the migration rates of human cancer cells and increase the sensitivity of metastasizing human A549 NSCLC cells and infiltrating human glioblastoma cells to cytotoxic insults of either proapoptotic or proautophagic drugs.[1] in vivo: 4-IBP increases the antitumor effects of temozolomide and irinotecan in immunodeficient mice that were orthotopically grafted with invasive cancer cells.[1]
References:
[1]. Mégalizzi V, et al. 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia. 2
- Hierochin D
Catalog No.:BCN1702
CAS No.:155759-02-7
- Peujaponiside
Catalog No.:BCN8261
CAS No.:155740-16-2
- Pizotifen
Catalog No.:BCC4215
CAS No.:15574-96-6
- Mecarbinate
Catalog No.:BCC4919
CAS No.:15574-49-9
- Isomagnolone
Catalog No.:BCN1701
CAS No.:155709-41-4
- Simonsinol
Catalog No.:BCN1700
CAS No.:155709-40-3
- Notoginsenoside Ft1
Catalog No.:BCN6434
CAS No.:155683-00-4
- PG-9 maleate
Catalog No.:BCC6779
CAS No.:155649-00-6
- Dehydroaglaiastatin
Catalog No.:BCN1699
CAS No.:155595-93-0
- VUF 10166
Catalog No.:BCC5060
CAS No.:155584-74-0
- Hydroxyfasudil hydrochloride
Catalog No.:BCC1636
CAS No.:155558-32-0
- 3a-Epiburchellin
Catalog No.:BCN7015
CAS No.:155551-61-4
- 3-beta-O-(cis-p-Coumaroyl)corosolic acid
Catalog No.:BCN1553
CAS No.:155800-17-2
- 25-O-Methylalisol A
Catalog No.:BCN3456
CAS No.:155801-00-6
- 5-O-Methylhierochin D
Catalog No.:BCN4526
CAS No.:155836-29-6
- BW 373U86
Catalog No.:BCC5798
CAS No.:155836-50-3
- RJR-2403
Catalog No.:BCC1901
CAS No.:15585-43-0
- 9,10-Dimethoxycanthin-6-one
Catalog No.:BCN3106
CAS No.:155861-51-1
- LE 135
Catalog No.:BCC7242
CAS No.:155877-83-1
- Gipsoside
Catalog No.:BCN8482
CAS No.:15588-68-8
- Edultin
Catalog No.:BCC8321
CAS No.:15591-75-0
- Rabdoternin F
Catalog No.:BCN6399
CAS No.:155977-87-0
- 4-Hydroxyphenylacetic acid
Catalog No.:BCN4795
CAS No.:156-38-7
- Sodium butyrate
Catalog No.:BCC4720
CAS No.:156-54-7
4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs.[Pubmed:17534441]
Neoplasia. 2007 May;9(5):358-69.
Although the molecular function of sigma receptors has not been fully defined and the natural ligand(s) is still not known, there is increasing evidence that these receptors and their ligands might play a significant role in cancer biology. 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP), a selective sigma1 agonist, has been used to investigate whether this compound is able to modify: 1) in vitro the migration and proliferation of human cancer cells; 2) in vitro the sensitivity of human glioblastoma cells to cytotoxic drugs; and 3) in vivo in orthotopic glioblastoma and non-small cell lung carcinoma (NSCLC) models the survival of mice co-administered cytotoxic agents. 4-IBP has revealed weak antiproliferative effects on human U373-MG glioblastoma and C32 melanoma cells but induced marked concentration-dependent decreases in the growth of human A549 NSCLC and PC3 prostate cancer cells. The compound was also significantly antimigratory in all four cancer cell lines. This may result, at least in U373-MG cells, from modifications to the actin cytoskeleton. 4-IBP modified the sensitivity of U373-MG cells in vitro to proapoptotic lomustin and proautophagic temozolomide, and markedly decreased the expression of two proteins involved in drug resistance: glucosylceramide synthase and Rho guanine nucleotide dissociation inhibitor. In vivo, 4-IBP increased the antitumor effects of temozolomide and irinotecan in immunodeficient mice that were orthotopically grafted with invasive cancer cells.
Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands.[Pubmed:11588125]
Br J Pharmacol. 2001 Oct;134(3):691-9.
1. Sigma receptors were first described in 1976 as opiate receptors but were later determined to be a distinct class of receptors with two subtypes, sigma(1) and sigma(2). Although the endogenous ligand is yet to be elucidated, the sigma(1) receptor has recently been cloned. 2. Behavioural models used to test potential antidepressants have shown sigma ligands to produce antidepressant effects but their mechanism of action is unknown. 3. The goal of the present study was to assess the effects of various sigma(1) ligands on the firing activity of serotonin (5-HT) neurons of the dorsal raphe nucleus (DRN) using extracellular in vivo recordings in anaesthetized rats. 4. The sigma(1) ligands (+)-pentazocine and 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP) (2 mg kg(-1) day(-1)) increased markedly 5-HT firing activity after 2 days of treatment and maintained the same increased firing rate after long-term (21 days) treatments. Furthermore, the increased firing rate produced by 2 and 21 day treatments with (+)-pentazocine was prevented by the co-administration of N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)-thylamine (NE-100) (10 mg kg(-1) day(-1)) a selective sigma(1) antagonist, confirming the sigma(1) receptor's modulation of these effects. In contrast, the sigma(1) ligands (+)-N-cyclopropylmethyl-N-methyl-1,4-diphenyl-1-1-ethyl-but-3-en-1-ylamine hydrochloride (JO-1784) and 2-(4-morpholinoethyl 1-phenyl-cyclohexane-1-carboxylate hydrochloride (PRE-084) had no effect. 5. Following a 21-day treatment with (+)-pentazocine there was a marked reduction in the number of neurons found per track. This decrease was not seen after chronic treatment with 4-IBP and may represent a depolarization block. 6. These results suggest a modulation of serotonergic neurotransmission by some sigma receptors and provide a potential mechanism for the 'antidepressant effects' reported and provide evidence toward sigma(1) ligands as potential antidepressants with a rapid onset of action.
Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition.[Pubmed:9223571]
J Pharmacol Exp Ther. 1997 Jul;282(1):326-38.
Recent studies propose that sigma site ligands antagonize N-methyl-D-aspartate (NMDA) receptors by either direct, or indirect mechanisms of inhibition. To investigate this question further we used electrical recordings to assay actions of seventeen structurally diverse sigma site ligands on three diheteromeric subunit combinations of cloned rat NMDA receptors expressed in Xenopus oocytes: NR1a coexpressed with either NR2A, 2B or 2C. The sigma site ligands had a wide range of potency for antagonizing NMDA receptor currents. Steady-state IC50 values ranged between approximately 0.1 to >100 microM. In all cases inhibition was non-competitive with respect to glycine and glutamate. Five structurally related sigma ligands [eliprodil, haloperidol, ifenprodil, 4-phenyl-1-(4-phenylbutyl)-piperidine and trifluperidol] were strongly selective for NR1a/2B receptors. The other drugs were weakly selective or nonselective inhibitors. There was no correlation between sigma site affinity and potency of NMDA receptor antagonism for any subunit combination. Inhibition of NR1a/2B receptors by the selective antagonists was independent of voltage whereas inhibition by the weakly selective antagonists was voltage dependent. Potency of 10 sigma ligands was cross-checked on NMDA currents in cultured rat cortical neurons. There was close correspondence between the two assay systems. Our results argue that antagonism of NMDA receptor currents by the sigma ligands tested is due to direct effects on the receptor channel complex as opposed to indirect effects mediated by sigma receptors. Inhibition occurs via sites in the NMDA receptor channel pore, or via allosteric modulatory sites associated with the NR2B subunit.